Evicenter
MarkdownMedical informationP&T meetings
Barzolvolimab (CDX-0159)

Chronic spontaneous urticaria

Launch
Not announced
Last updated
177 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Heterogeneity of treatment effect

14 evidence topics · 17 sources

Barzolvolimab phase 3: complete response (UAS7=0) at Week 12, overall and in omalizumab-refractory participants
Population and arm, Week 12EMBARQ-CSU1EMBARQ-CSU2
Overall, placebo“9.3%”“12.6%”
Overall, 150 mg Q4W“42.4% (p<.00001)”“45.7% (p<.00001)”
Overall, 300 mg Q8W“42.1% (p<.00001)”“44.0% (p<.00001)”
Omalizumab-refractory, placebo“9.3%”“15.1%”
Omalizumab-refractory, 150 mg Q4W“55.3% (p<.00001)”“41.7% (p=.0089)”
Omalizumab-refractory, 300 mg Q8W“44.3% (p=.00017)”“46.4% (p=.0036)”
International guideline: biomarkers of response to omalizumab, dupilumab, ciclosporin, and antihistamines